Basilea Pharmaceutica’s (Basilea) anti-infective compounds ceftobiprole, isavuconazole and the novel antibiotic BAL30072’s data were presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
The data demonstrated that the in-vitro potency of BAL30072 translates into high efficacy in in-vivo models for respiratory tract infection (RTI), urinary tract infection (UTI), septicemia and for soft tissue infection (STI) involving multi-resistant Gram-negative “superbugs”.
Reportedly, new in-vitro data demonstrate BAL30072’s activity against clinically increasingly problematic multi-resistant Pseudomonas and Acinetobacter spp. as well as against Burkholderia pseudomallei.
Weiss and co-authors has demonstrated that BAL30072’s strong bactericidal activity in vitro translates into efficacy against Klebsiella pneumoniae and Pseudomonas aeruginosa in RTI models comparable to that of the therapeutic benchmark meropenem.
Additionally, high activity was also shown in models for STI against Acinetobacter baumannii by Russo and co-authors. Further BAL30072 shows good efficacy against Gram-negative pathogens in models for blood infection and for UTI (Escherichia coli).
The data from the infection models confirm the compatibility and synergistic effects of BAL30072 with carbapenems observed in a number of in-vitro studies.
BAL30072 is a novel siderophore monobactam that acts like a “Trojan horse” by exploiting natural nutrient uptake systems to gain access to its target. Its unique pattern of penicillin-binding-protein inhibition and its bactericidal mode of action confer potent in-vitro activity against Gram-negative fermentors and non-fermentors, claims the company.